Adjuvant Therapy in Pancreatic Cancer

1999 ◽  
pp. 431-443
Author(s):  
Paula Ghaneh ◽  
Anthony Kawesha ◽  
J. D. Evans ◽  
J. P. Neoptolemos
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy

scholarly journals Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: a systematic review

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dominic O’Connor ◽  
Malcolm Brown ◽  
Martin Eatock ◽  
Richard C. Turkington ◽  
Gillian Prue
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Pancreatic Cancer ◽  
Adjuvant Therapy ◽  
Physical Function ◽  
Meta Analysis ◽  
Ductal Adenocarcinoma ◽  
Key Stakeholders ◽  
The Impact

Abstract Background Surgical resection remains the only curative treatment for pancreatic cancer and is associated with significant post-operative morbidity and mortality. Patients eligible for surgery, increasingly receive neo-adjuvant therapy before surgery or adjuvant therapy afterward, inherently exposing them to toxicity. As such, optimizing physical function through exercise during treatment remains imperative to optimize quality of life either before surgery or during rehabilitation. However, current exercise efficacy and prescription in pancreatic cancer is unknown. Therefore, this study aims to summarise the published literature on exercise studies conducted in patients with pancreatic cancer undergoing treatment with a focus on determining the current prescription and progression patterns being used in this population. Methods A systematic review of four databases identified studies evaluating the effects of exercise on aerobic fitness, muscle strength, physical function, body composition, fatigue and quality of life in participants with pancreatic cancer undergoing treatment, published up to 24 July 2020. Two reviewers independently reviewed and appraised the methodological quality of each study. Results Twelve studies with a total of 300 participants were included. Heterogeneity of the literature prevented meta-analysis. Exercise was associated with improvements in outcomes; however, study quality was variable with the majority of studies receiving a weak rating. Conclusions High quality evidence regarding the efficacy and prescription of exercise in pancreatic cancer is lacking. Well-designed trials, which have received feedback and input from key stakeholders prior to implementation, are required to examine the impact of exercise in pancreatic cancer on key cancer related health outcomes.

scholarly journals New Techniques and Agents in the Adjuvant Therapy of Pancreatic Cancer

2002 ◽  
Vol 41 (7-8) ◽  
pp. 582-595 ◽  
Author(s):  
Michael G. T. Raraty ◽  
Conor J. Magee ◽  
Paula Ghaneh ◽  
John P. Neoptolemos
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy ◽  
New Techniques

Role of Adjuvant Therapy in the Management of Pancreatic Cancer

2005 ◽  
Vol 39 ◽  
pp. 223-244 ◽  
Author(s):  
Dan Laheru ◽  
Charles J. Yeo
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy

scholarly journals Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer

2019 ◽  
Vol 27 (3) ◽  
pp. 507-517 ◽  
Author(s):  
Manisit Das ◽  
Limei Shen ◽  
Qi Liu ◽  
Tyler J. Goodwin ◽  
Leaf Huang
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy ◽  
Nanoparticle Delivery

scholarly journals Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer

2008 ◽  
Vol 7 (8) ◽  
pp. 2464-2475 ◽  
Author(s):  
Ute Distler ◽  
Jamal Souady ◽  
Marcel Hülsewig ◽  
Irena Drmić-Hofman ◽  
Jörg Haier ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy

Adjuvant Therapy in Pancreatic Cancer: A Critical Appraisal – The Authors’ Reply

Drugs ◽  
2007 ◽  
Vol 67 (17) ◽  
pp. 2491-2493
Author(s):  
Helmut Oettle ◽  
Peter Neuhaus
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy ◽  
Critical Appraisal

Effectiveness of Adjuvant Therapy in Patients with Pancreatic Cancer Who Underwent Neoadjuvant Therapy

2021 ◽  
Author(s):  
Hiroshi Kurahara ◽  
Yuko Mataki ◽  
Tetsuya Idichi ◽  
Satoshi Iino ◽  
Yota Kawasaki ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy ◽  
Neoadjuvant Therapy

Adjuvant and Neoadjuvant Therapy for Pancreatic Adenocarcinoma

2017 ◽  
Author(s):  
Gregory C Wilson ◽  
Brent T Xia ◽  
Syed A Ahmed
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy ◽  
Neoadjuvant Therapy ◽  
Pancreatic Adenocarcinoma ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Advanced Pancreatic Cancer ◽  
Treatment Strategies ◽  
Ductal Adenocarcinoma ◽  
Borderline Resectable

Despite decades of advancement and research into the multimodal care of pancreatic cancer, mortality after the diagnosis of pancreatic ductal adenocarcinoma remains grim. The role of adjuvant therapy following surgical resection has been well established in the literature. However, adjuvant therapy is imperfect, and outside of a clinical trial, there are high rates of omission or delayed initiation of therapy. Neoadjuvant treatment strategies continue to be explored in the management of resectable, borderline-resectable, and locally advanced unresectable pancreatic adenocarcinoma. With improved resection rates and the possibility for tumor downstaging, neoadjuvant therapy has become standard for patients with borderline-resectable and locally advanced unresectable tumors. Additional benefits of neoadjuvant therapy in the treatment of resectable tumors include improved completion rates of systemic therapy and R0 resection rates. Future clinical trials, including the use of novel treatment agents and combination treatment strategies in both neoadjuvant and adjuvant regimens, will add value to the treatment of pancreatic adenocarcinoma. Key words: adjuvant therapy, borderline-resectable pancreatic cancer, locally advanced pancreatic cancer, neoadjuvant therapy, pancreatic adenocarcinoma, resectable disease 

Sign in / Sign up

Export Citation Format

Share Document